Involvement of Adrenomedullin Expression in Tumor Cells and Stroma in the Development of Diabetes in Pancreatic Cancer Patients

Hideyuki IMAI*1,2,3, Nobuyuki OHIKE2, Tomoko NOROSE2, Tomohide ISOBE3, Koichiro FUJIMASA1,2, Masatsugu NAGAHAMA4, Jun-ichi TANAKA5, Shoichiro NAGASAKA3 and Masafumi TAKIMOTO1

Abstract: Some studies have reported that adrenomedullin (AM) is involved in diabetes mellitus (DM) associated with pancreatic cancer. Therefore, in this study we investigated the relationship between diabetes and AM expression in patients with pancreatic cancer. We examined 48 biopsies and 26 surgical resections from 74 patients with histologically diagnosed pancreatic cancer. Patients were classified into either DM or non-DM groups. The immunohistochemical expression of AM and various clinicopathological factors were compared between the two groups. Among the biopsy cases, 21 were classified as DM and 27 as non-DM. AM expression in pancreatic cancer cells was significantly lower in the DM group \(p = 0.03\). No significant differences were noted in age, body mass index, tumor diameter or location, serum CA19-9, amylase, or C-reactive protein levels, pancreatic ductal dilatation, portal vein invasion, clinical stage, or histological differentiation between the DM and non-DM groups. The proportion of men was significantly lower in the DM group \(p = 0.04\), as was the frequency of liver metastasis at diagnosis \(p = 0.03\). Among the resection cases, 13 were classified as DM and 13 as non-DM. There were no significant differences in AM expression in pancreatic cancer cells between the two groups. However, marked AM expression was observed in the inflammatory cells and fibroblasts of the tumor stroma in all cases. In addition, the inflammatory response in the tumor stroma tended to be stronger in the DM group. Although the present study failed to find a positive correlation between diabetes and AM expression in pancreatic cancer cells, the results indicate that AM expression in stromal cells may be more closely related to the development of DM in pancreatic cancer patients.

Key words: diabetes mellitus, pancreatic cancer, adrenomedullin, inflammation, immunohistochemical study

1) Department of Pathology and Laboratory Medicine, Showa University School of Medicine, 1-5-8 Hatanodai, Shinagawa-ku, Tokyo 142-8555, Japan.
2) Department of Pathology and Laboratory Medicine, Showa University Fujigaoka Hospital.
3) Department of Medicine, Division of Diabetes, Metabolism and Endocrinology, Showa University Fujigaoka Hospital.
4) Department of Medicine, Division of Gastroenterology, Showa University Fujigaoka Hospital.
5) Department of Surgery, Division of General and Gastroenterological Surgery, Showa University Fujigaoka Hospital.

* To whom correspondence should be addressed.
Introduction

The relationship between diabetes mellitus (DM) and pancreatic cancer (PC) has long been considered. The prevalence of diabetes in PC patients is high, ranging from approximately 40% to 55%.1-3 Long-standing diabetes is regarded as a risk factor for PC, whereas PC is thought to cause diabetes and glucose tolerance. Diabetes frequently improves after surgical resection of PC,2-4 and Pannala et al reported that diabetes improved after pancreatectomy in 57% of PC patients with new-onset diabetes.2 These facts suggest that PC itself may cause diabetes, but the underlying mechanism remains unclear.

One possible mechanism is thought to be the secretion, by tumors, of diabetogenic products that cause diabetes,5 including adrenomedullin (AM), islet amyloid polypeptide, and S-100A8 N-terminal peptide.6,7 AM, a 52-amino acid multifunctional hormone, was originally identified as a hypotensive peptide isolated from pheochromocytoma and subsequently shown to exert proliferative and proangiogenic effects.8 AM inhibits insulin secretion from pancreatic islets and causes glucose tolerance in vivo and in vitro.9 Recent studies have reported that AM expression in PC cells is a likely candidate for the induction of diabetes in patients with PC.5,7,10 The main purpose of the present study was to investigate the relationship between the presence or absence of diabetes and the expression of AM in PC cells.

Materials and methods

The study was performed on 48 patients who had undergone a pancreatic biopsy by endoscopic ultrasound-guided fine needle aspiration and 26 who had undergone pancreatic surgical resection between 2014 and 2017 at the Showa University Fujigaoka Hospital. All patients had been histopathologically diagnosed with typical pancreatic cancer (tubular adenocarcinoma). Patients were divided into two groups based on serum HbA1c levels at the time of diagnosis and their history of diabetes: (i) a DM group, with HbA1c ≥ 6.5% and no history of diabetes or HbA1c ≥ 8.0% and a history of diabetes; and (ii) a non-DM group without these abnormalities. Among the biopsied cases, 21 were classified as DM and 27 as non-DM; among the resected cases, 13 were classified as DM and 13 as non-DM.

Clinicopathological features (i.e. patient age, gender, body mass index [BMI], tumor size, location, serum concentrations of carbohydrate antigen 19-9 [CA19-9], amylase, and C-reactive protein [CRP], dilatation of the pancreatic duct, invasion to the portal vein, liver metastasis, clinical stage, and histological differentiation) were investigated in the patients who underwent pancreatic biopsy and were compared between the DM and non-DM groups. Tumor size, location, dilatation of the pancreatic duct, invasion to the portal vein, and liver metastasis were evaluated by computed tomography (CT) or magnetic resonance imaging (MRI). Clinical stage was classified according to the criteria issued by the Japan Pancreas Society.11

For the immunohistological investigation of AM expression, 3-µm sections were obtained from each formalin-fixed, paraffin-embedded block. Immunohistochemical staining was performed using the avidin–biotin complex detection system with a BEKCHMARK automated immunostaining
device (Ventana Medical Systems, Tucson, AZ, USA). A rabbit anti-human AM polyclonal antibody (200-fold dilution; abcam, Cambridge, UK) was used. The staining intensity of AM expression in tumor cells was classified as mild (0), moderate (1+), or severe (2+), as shown in Fig. 1, and was compared between the DM and non-DM groups for both biopsied and resected cases.
In surgical specimens, AM expression was observed in the tumor stroma (Fig. 2) and the degree of inflammation was investigated and classified as follows: mild \((0)\), scant infiltration of inflammatory cells; moderate \((1+)\), intermediate infiltration; and severe \((2+)\), prominent infiltration of inflammatory cells containing many lymph follicles (Fig. 3). The degree of inflammation was compared between the DM and non-DM groups. In addition, we investigated whether there were significant relationships between serum HbA1c, diabetic status (i.e. DM or non-DM group), the degree of AM expression in tumor cells, and the degree of inflammation. Pathological scoring was performed by two pathologists (H.I. and N.O.) in a blinded manner. Statistical analyses were performed using the \(\chi^2\) test, Fisher’s exact test, or Wilcoxon’s rank sum test. Two-tailed \(p < 0.05\) was considered significant.

The present study was a retrospective study, and consent was obtained by opt-out. Information regarding the study was posted on the Showa University Fujigaoka Hospital homepage. Subjects were guaranteed the opportunity to opt-out of the study. Approval for this study was obtained from the Ethics Committee at Showa University Fujigaoka Hospital (Permission no. F2017C62).

**Results**

**Clinicopathological comparisons between the DM and non-DM groups (pancreatic biopsies)**

Clinicopathological factors in the DM \((n=21)\) and non-DM \((n=27)\) groups were compared for biopsy cases (Table 1). The non-DM group included three patients who had a history of diabetes but did not meet the criteria of the DM group. In the DM and non-DM groups,

|                                      | DM group \((n=21)\) | Non-DM group \((n=27)\) | \(p\)-value |
|--------------------------------------|---------------------|--------------------------|------------|
| Age (years)                          | 71 [65.5–75]        | 72 [68–79]               | 0.3        |
| Male                                 | 7 (33)              | 17 (63)                  | 0.04       |
| BMI (kg/m²)                          | 21.2 [18.6–21.9]    | 20.6 [17.4–22.1]         | 0.63       |
| Tumor size (mm)                      | 33 [20–40]          | 34 [29–47]               | 0.65       |
| Location pancreatic head             | 12 (57)             | 10 (37)                  | 0.17       |
| CA19-9 (U/ml)                        | 724 [107–2,840]     | 1,144 [292–9,640]        | 0.29       |
| Amylase (IU/l)                       | 58 [45.5–107]       | 72 [50–118]              | 0.48       |
| CRP (mg/dl)                          | 0.14 [0.04–0.50]    | 0.12 [0.05–0.77]         | 0.61       |
| Dilatation of pancreatic duct ≥ 5 mm| 11 (52)             | 9 (33)                   | 0.18       |
| Invasion to portal vein              | 4 (19)              | 9 (33)                   | 0.27       |
| Liver metastasis                     | 5 (24)              | 15 (56)                  | 0.03       |
| Clinical Stage IV                    | 14 (67)             | 21 (78)                  | 0.39       |
| Poorly differentiated histologically | 3 (14)              | 2 (7)                    | 0.64       |

Data are expressed as the median [25th–75th percentile] or as the number of patients (%). BMI, body mass index; CA19-9, carbohydrate antigen 19-9; CRP, C-reactive protein.
respectively, the median age was 71 and 72 years, 33% and 63% of patients were male, median BMI was 21.2 and 20.6 kg/m², and median tumor diameter was 33 and 34 mm. When the tumor location was classified into pancreatic head versus body and tail, 57% and 37% of tumors were located in the head in the DM and non-DM groups, respectively. In the DM and non-DM groups, respectively, median serum CA19-9 was 724 and 1,144 U/ml, median amylase was 58 and 72 IU/l, and median CRP levels were 0.14 and 0.12 mg/dl. The number of significant dilatations (≥5 mm in diameter) of the main pancreatic duct was 11 (52%) and 9 (33%) in the DM and non-DM groups, respectively, whereas the number of patients in the DM and non-DM groups with invasion to the portal vein was 4 (19%) and 9 (33%), respectively, and 5 (24%) and 15 (56%) patients, respectively, had liver metastases. The number of clinical Stage IV cases in the DM and non-DM groups was 14 (67%) and 21 (78%), respectively, and there were 3 (14%) and 2 (7%) cases with poorly differentiated adenocarcinoma in these two groups, respectively. Significant differences were found with regard to gender (p = 0.04) and liver metastasis (p = 0.03). The DM group tended to be more frequently diagnosed with PC due to new-onset diabetes or elevated blood glucose before developing liver metastasis.

**AM expression in tumor cells from pancreatic biopsy or surgically resected specimens**

Immunohistochemical analysis revealed uniform AM staining throughout the lesions in all cases, but of varying degree. In biopsy cases, mild (0), moderate (1+), and severe (2+) AM expression was found in tumor cells in 6 (28%), 10 (48%), and 5 (24%) cases in the DM group, respectively, compared with 2 (7%), 12 (45%), and 13 (48%) cases in the non-DM group (Fig. 4A). AM expression was significantly lower in the DM than in the non-DM group (p = 0.03). In surgically
In surgically resected specimens, there were 4 (31%), 4 (31%), and 5 (38%) cases of mild (0), moderate (1+), and severe (2+) AM expression in tumor cells, respectively, in the DM group, compared with 4 (31%), 6 (46%), and 3 (23%) cases in the non-DM group (Fig. 4B). There were no significant differences in AM staining intensity between the two groups \( p = 0.64 \).

**Inflammation of the tumor stroma in surgically resected specimens**

Significant AM expression was observed in inflammatory cells and fibroblasts in the tumor stroma. In particular, AM expression was prominent in lymph follicles. There were 2 (15%), 3 (23%), and 8 (62%) cases of mild (0), moderate (1+), and severe (2+) inflammation of the tumor stroma, respectively, in the DM group, compared with 3 (23%), 6 (46%), and 4 (31%) in the non-DM group (Fig. 5). These observations suggest that the inflammatory response of the tumor stroma tended to be stronger in the DM than in the non-DM group, although the difference was not statistically significant \( p = 0.18 \).

**Relationships between serum HbA1c, group, the degree of AM expression in tumor cells, and the degree of inflammation in surgically resected specimens**

As indicated in Table 2, there were no significant differences in serum HbA1c, DM group, and inflammation of the tumor stroma between different grades of AM expression in tumor cells. In addition, there were no significant differences in serum HbA1c, DM group, and AM expression in tumor cells between different grades of inflammation of the tumor stroma (Table 3). However, there was a tendency for a greater number of cases in the DM group to exhibit stronger inflammation of the tumor stroma \( p = 0.12 \).
Discussion

The underlying mechanism and pathogenesis of PC-induced diabetes remain unclear. Previous reports have suggested direct destruction of islet cells or a decrease in the number of islet cells as a result of PC invasion and/or PC-associated obstructive pancreatitis and fibrosis\textsuperscript{12,13}. However, diabetes frequently improves after surgical resection of PC, and even small tumors cause glucose tolerance; therefore, it seems difficult to attribute the pathogenesis of DM only to the destruction of or a decrease in the number of islet cells\textsuperscript{2,7}. The biopsy case study reported herein also showed no significant differences in factors related to tumor development, such as tumor size and dilatation of the pancreatic duct, between the DM and non-DM groups.
Several diabetogenic tumor-secreted products are hypothesized to be involved in PC-associated diabetes\textsuperscript{6,7}, including AM\textsuperscript{5,7,10,14}. AM is a multifunctional hormone expressed in various tissues of the human body. In the pancreas, AM receptors are found on β-cells, and AM expression is found in pancreatic polypeptide cells of the islets\textsuperscript{15}. Furthermore, AM inhibits insulin secretion from islets and causes glucose tolerance in in vivo and in vitro in rat models\textsuperscript{9}.

Ramachandran et al\textsuperscript{16} showed that AM is expressed in PC and it stimulates cell proliferation and invasion in an autocrine manner via the AM receptor\textsuperscript{16}. Aggarwal et al\textsuperscript{10}, using both in vivo and in vitro experiments, showed that AM is upregulated in patients with PC and it mediates PC-induced inhibition of insulin section in β-cells. AM levels are higher in patients with PC who developed diabetes compared to those who did not\textsuperscript{10}. In contrast to our expectations, in the present study we failed to find a significantly higher AM expression in the DM group, in either the biopsy or resection cases; rather, we found that the AM expression was significantly lower in the DM than in the non-DM group.

To determine the cause of this unexpected result, we focused on AM expression in surgically resected specimens; in these specimens, in almost all cases, AM expression was more prominent in the inflammatory cells (especially lymph follicles) and fibroblasts of the tumor stroma than in PC cells. Although the differences were not significant, we did find a stronger inflammatory response in the DM than in the non-DM group, suggesting that AM expression in response to inflammation may be more closely related to the development of diabetes in PC patients, as reported previously\textsuperscript{6,7,17}. Regarding fibroblasts, Bhowmick et al\textsuperscript{18} showed that stromal fibroblasts in tumors are biologically distinct from normal fibroblasts, and Benyahia et al\textsuperscript{19} reported that stromal fibroblasts in breast cancer promote tumor growth and angiogenesis through AM secretion. We expect that the AM expression of stromal fibroblasts in PC will be found to have multiple functions and to be associated with the onset of diabetes.

In conclusion, the present study failed to find a positive correlation between diabetes and AM expression in PC cells. Conversely, the inflammatory response in the tumor stroma tended to be stronger in the DM group, although the difference was not statistically significant. Therefore, the findings of the present study indicate that AM expression in inflammatory tissues may be one of the potential mechanisms by which PC induces diabetes.

Conflict of interest statement

The authors declare no conflicts of interest in association with this study.

References

1) Chari ST, Leibson CL, Rabe KG, et al. Pancreatic cancer-associated diabetes mellitus: prevalence and temporal association with diagnosis of cancer. Gastroenterology. 2008;134:95–101.
2) Pannala R, Leirness JB, Bamlet WR, et al. Prevalence and clinical profile of pancreatic cancer-associated diabetes mellitus. Gastroenterology. 2008;134:981–987.
3) Wakasugi H, Funakoshi A, Iguchi H. Clinical observations of pancreatic diabetes caused by pancreatic carcinoma, and survival period. Int J Clin Oncol. 2001;6:50–54.
4) Permert J, Ihse I, Jorfeldt L, et al. Improved glucose metabolism after subtotal pancreatectomy for pancreatic cancer. Br J Surg. 1993;80:1047–1050.
5) Gorgulu K, Diakopoulos KN, Vatansever HS. A star of connection between pancreatic cancer and diabetes: adrenomedullin. JOP. 2015;16:408–412. (accessed 2015 Sep 8) Available from: http://pancreas.imedpub.com/a-star-of-connection-between-pancreatic-cancer-and-diabetesadrenomedullin.pdf.
6) Andersen DK, Korc M, Petersen GM, et al. Diabetes, pancreatogenic diabetes, and pancreatic cancer. Diabetes. 2017;66:1103–1110.
7) Sah RP, Nagpal SJ, Mukhopadhyay D, et al. New insights into pancreatic cancer-induced paraneoplastic diabetes. Nat Rev Gastroenterol Hepatol. 2013;10:423–433.
8) Ishimitsu T, Nishikimi T, Saito Y, et al. Plasma levels of adrenomedullin, a newly identified hypotensive peptide, in patients with hypertension and renal failure. J Clin Invest. 1994;94:2158–2161.
9) Martinez A, Weaver C, Lopez J, et al. Regulation of insulin secretion and blood glucose metabolism by adrenomedullin. Endocrinology. 1996;137:2626–2632.
10) Aggarwal G, Ramachandran V, Javeed N, et al. Adrenomedullin is up-regulated in patients with pancreatic cancer and causes insulin resistance in beta cells and mice. Gastroenterology. 2012;143:1510–1517.
11) Japan Pancreas Society, ed. General rules for the study of pancreatic cancer. 7th ed. Tokyo: Kanehara; 2016. (in Japanese).
12) Kaji H, Inoue K, Miyashita T, et al. Relationship between glucose tolerance and quantitative changes of islet cells in chronic obstructive pancreatitis due to pancreaticoduodenal cancer. Am J Gastroenterol. 1991;86:1020–1026.
13) Kloppel G, Bommer G, Commandeur G, et al. The endocrine pancreas in chronic pancreatitis. Immunocytochemical and ultrastructural studies. Virchows Arch A Pathol Anat Histol. 1978;377:157–174.
14) Schmied BM, Ulrich AB, Matsuzaki H, et al. Alteration of the Langerhans islets in pancreatic cancer patients. Int J Pancreatol. 2000;28:187–197.
15) Hong Y, Hay DL, Quirion R, et al. The pharmacology of adrenomedullin 2/intermedin. Br J Pharmacol. 2012;166:110–120.
16) Ramachandran V, Arumugam T, Hwang RF, et al. Adrenomedullin is expressed in pancreatic cancer and stimulates cell proliferation and invasion in an autocrine manner via the adrenomedullin receptor, ADMR. Cancer Res. 2007;67:2666–2675.
17) Hirata Y, Mitaka C, Sato K, et al. Increased circulating adrenomedullin, a novel vasodilatory peptide, in sepsis. J Clin Endocrinol Metab. 1996;81:1449–1453.
18) Bhowmick NA, Neilson EG, Moses HL. Stromal fibroblasts in cancer initiation and progression. Nature. 2004;432:332–337.
19) Benyahia Z, Dussault N, Cayol M, et al. Stromal fibroblasts present in breast carcinomas promote tumor growth and angiogenesis through adrenomedullin secretion. Oncotarget. 2017;8:15744–15762.

[Received February 28, 2018 : Accepted April 9, 2018]